TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05891769
Drug: 18Fluorocholine
Normalized name: fluorocholine (18F)
DrugBank: Fluorocholine F-18 (DB15887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F Fluorocholine 5 mCi ± 20% administered intravenously.
Study: NCT05496465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single treatment of placebo nasal spray
Study: NCT05434104
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
Study: NCT06045000
Drug: [14C]-DC-806
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04739592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once per week for one year
Study: NCT05307874
Drug: Proleukin Injectable Product
Normalized name: Proleukin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
Study: NCT06451666
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study: NCT06705842
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgeons may utilize local irrigation with saline if deemed necessary, defined as instillation of a small volume (\<100 mL) of liquid followed by aspiration, for the purpose of confirming hemostasis or suctioning thick fluid. Some surgeons may utilize large volume irrigation with saline solution, if that is consistent with their usual practice. Patients in the usual care arm will not receive PVI irrigation.
Study: NCT06439082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Study: NCT05802303
Drug: 17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
Study: NCT05802303
Drug: Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)
Normalized name: estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
Study: NCT06199427
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
Study: NCT05743777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
Study: NCT04728698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume of placebo will be administered
Study: NCT06238219
Drug: Neuromuscular Blocking Agent
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of any neuromuscular blocking agent for surgery under general anesthesia
Study: NCT05485480
Drug: conventional opioid-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
Study: NCT05485480
Drug: opioid-sparing group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
Study: NCT00203697
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04847583
Drug: COVID-19 Standard of care
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator
Study: NCT06500429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Including placebo
Study: NCT00001013
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04835064
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
Study: NCT06541678
Drug: Danuglipron
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR Tablet
Study: NCT05206110
Drug: 10 mg IV ketorolac
Normalized name: ketorolac 10 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
Study: NCT05206110
Drug: 30 mg IV ketorolac
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
Study: NCT04062721
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
Study: NCT05603572
Drug: KAT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosage form
Study: NCT05603572
Drug: KAT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT dosage form
Study: NCT00281723
Drug: Pro-Pe adhesive tablet
Normalized name: ADHESIVE,PROS-AIDE II
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06110598
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
Study: NCT05388656
Drug: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release
Normalized name: Estradiol Patch, 0.1 mg/24 hours weekly transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/day transdermal patch administered for 3 weeks
Study: NCT05388656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-matched placebo patch administered for 3 weeks
Study: NCT06681402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation
Study: NCT06342856
Drug: co enzyme Q10 , L- Carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
Study: NCT05298683
Drug: Acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
Study: NCT06611501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
Study: NCT06613178
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
Study: NCT02992756
Drug: Growth Factors
Normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose 3-6 mL of PRP obtained by PRGF Endoret
Study: NCT04536675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Study: NCT05183347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06693609
Drug: EMP-01 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMP-01 placebo capsules
Study: NCT06326086
Drug: Targeted Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted agents as prescribed by primary treating physician
Study: NCT06326086
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy as prescribed by primary treating physician
Study: NCT04921969
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
Study: NCT05654064
Drug: Remifentanil-dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Study: NCT05654064
Drug: Dexmedetomidine-fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Study: NCT05463497
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: JW0201: single administration, Tablet, Oral, BID for 5 days
Study: NCT05463497
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2103: single administration, Tablet, Oral, BID for 5 days
Study: NCT04676724
Drug: PegIFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered PegIFN.
Study: NCT05225389
Drug: 300 mg [C14] CT1812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
Study: NCT05038449
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
Study: NCT06279195
Drug: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be instructed to take REL-CT.
Study: NCT00063804
Drug: AMD070
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06319729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06714396
Drug: QRL-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Study: NCT06704594
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.
Study: NCT06613152
Drug: HS-IT201 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study: NCT05803759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules manufactured to mimic Allicor 150 mg capsules
Study: NCT05102071
Drug: sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfonylurea
Study: NCT06165237
Drug: BR6001-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT06165237
Drug: BR6001-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone, Once a day
Study: NCT05684289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06218771
Drug: TQB3454 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
Study: NCT06223308
Drug: HB0028
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
Study: NCT06002659
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-conditioning chemotherapy
Study: NCT06748053
Drug: GSK5784283
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK5784283 will be administered.
Study: NCT06748053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT00037063
Drug: Thiamine hydrochloride
Normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00037063
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04928144
Drug: SHJ - Mid concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic
Study: NCT05460858
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06360965
Drug: Improved warm meridians and relieve pain plaster
Normalized name: SOMBRA Warm Pain Relieving Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
Study: NCT06360965
Drug: Traditional warm meridians and relieve pain plaster
Normalized name: SOMBRA Warm Pain Relieving Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.
Study: NCT04260256
Drug: [18F]F-AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
Study: NCT06358118
Drug: Buyuan Zhixiao Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buyuan Zhixiao Formula
Study: NCT06358118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains 10% of the active ingredients of the Chinese medicine group
Study: NCT04369547
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to roflumilast capsule
Study: NCT05109117
Drug: CAP Unscented
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen lip balm.
Study: NCT04408664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
Study: NCT06052995
Drug: Elidel 1% Topical Cream
Normalized name: Elidel 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
Study: NCT00095342
Drug: TMI-005
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06452602
Drug: Induction immunochemotherapy followed by concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f.
Study: NCT01351090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal
Study: NCT05679453
Drug: Lornoxicam 8 Mg Oral Tablet
Normalized name: lornoxicam 8 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Study: NCT06101147
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
Study: NCT05642104
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
Study: NCT05141071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of saline will be administrated enterally
Study: NCT06671405
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 and Dose 2
Study: NCT06671405
Drug: Ethinyl estradiol/levonorgestrel
Normalized name: ETHINYL ESTRADIOL/LEVONORGESTREL
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Period 1 (EE and LNG administration only).~* Period 3 (AZD0780 + EE and LNG administration).
Study: NCT05429671
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
Study: NCT05429671
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
Study: NCT05547256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT06796907
Drug: GSK5733584
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK5733584 will be administered intravenously (IV).
Study: NCT06796907
Drug: Anticancer therapy 1
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticancer therapy 1 will be administered IV.
Study: NCT06796907
Drug: Anticancer therapy 2
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticancer therapy 2 will be administered IV.
Study: NCT06796907
Drug: Anticancer therapy 4
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticancer therapy 4 will be administered IV.
Study: NCT06184009
Drug: ALL, High risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported.
Study: NCT05076877
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
Study: NCT05655689
Drug: Gentamicin 1.4% + vancomycin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05497297
Drug: HSK7653 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK7653, tablet, oral
Study: NCT05593653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken at bedtime for 4 weeks
Study: NCT06136455
Drug: Listerine Total Care Zero Alcohol Mouthwash
Normalized name: Listerine Total Care Zero Alcohol Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
Study: NCT06765317
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 iv D1
Study: NCT06765317
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 iv D1
Study: NCT06458907
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy
Study: NCT05118620
Drug: Placebo normal saline PENG block
Approvals — FDA: no, EMA: no, PMDA: no
Description: A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
Study: NCT05377112
Drug: SYNB8802v1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites.